We use cookies on this site in order to make it works, and for the traffic analysis.
You can refuse or configure cookies by purposes.
Another message from the Google Adsense consent management platform will ask you for your choices relating to the use of your personal data via cookies for advertising.
We thank you to accept cookies which makes this site work.

Dealing with uncertainty in uveal melanoma prognostication

I am resident in Medical Oncology. Within the frame of my Master of Science in Medical Ethics, I am working on communicating prognosis in Uveal Melanoma patients.
As you know, practices and guidelines are heterogeneous between countries and ophthalmologists. Some do biopsies, other do not. Some propose prognostic signatures such as gene expression profile or cytogenetic signatures, some do not.

My main questions are how clinicians communicate prognosis and what are the factors influencing such communication.

To answer these questions, I would like to propose you a short anonymous survey that will take about five minutes.

mandatory answer

Question 1

Country of practice?

mandatory answer

Question 2

For how long have you been in the UM field?

Question 3

How many new patients with uveal melanoma do you take care of every year?

Question 4

How do you assess UM prognosis in routine practice?

Comments

mandatory answer

Question 5

Do you ask for consent before prognosis testing when an enucleation is recommended?

Comments

mandatory answer

Question 6

When accessible, do you perform a fine-needle aspiration biopsy (FNAB) in these case? If so, why?

Comments

Question 7

What information do you give to patients before performing FNAB?

Comments

Question 8

Do you ask for signed consent before FNAB?

Comments

mandatory answer

Question 9

To your opinion, how often patients ask for their prognosis?

mandatory answer

Question 10

Do you provide the patient with survival statistics?

Comments

Question 11

Do you personally explain to patients their metastatic risk level?

Comments

Question 12

Is Yes, how do you communicate prognosis in patients at high risk of metastatic recurrence?

Question 13

Is another health professional in charge of informing patients?

Question 14

If yes, who ?

Question 15

If you want to have the results of this survey, please provide us with your email




You too, create your online questionnaire!
It's free and easy.
Let's go!
▲